Zymeworks Inc. logo

Zymeworks Inc.

NYSE:ZYME

Overview | Financials
Company Name Zymeworks Inc.
Symbol ZYME
Currency USD
Price 14.24
Market Cap 980,815,600
Dividend Yield 0%
52-week-range 7.97 - 17.7
Industry Biotechnology
Sector Healthcare
CEO Mr. Kenneth H. Galbraith C.A.
Website https://www.zymeworks.com

An error occurred while fetching data.

About Zymeworks Inc.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and

Related Stocks

Rite Aid Corporation logo

Rite Aid Corporation

RAD

0.648 USD

ATI Physical Therapy, Inc. logo

ATI Physical Therapy, Inc.

ATIP

1 USD

Vicarious Surgical Inc. logo

Vicarious Surgical Inc.

RBOT

12.78 USD

Owlet, Inc. logo

Owlet, Inc.

OWLT

4.68 USD

Financials

Numbers are in millions USD

Numbers are in millions USD